Enhancements Offer Improved Performance for High Throughput Sequencing

SAN DIEGO--(BUSINESS WIRE)--Oct. 17, 2014-- Illumina, Inc. (NASDAQ:ILMN) today announced the launch of new reagent kits for the HiSeq X^TM Ten and HiSeq® 2500 Sequencing Systems, bringing further advancements to the most comprehensive next-generation sequencing portfolio. The kits advance the proven Illumina sequencing by synthesis (SBS) chemistry and boost the power and efficiency of HiSeq Systems. The reagent kits expand the range of possibilities available to researchers using Illumina sequencing technologies by offering superior data quality on the HiSeq X Ten System and longer read lengths on the HiSeq 2500 System.

For HiSeq X Ten Systems, the HiSeq X HD v2 Reagent Kit adds flexibility to population-scale human whole-genome sequencing by supporting an expanded menu of library preparation options while offering superior data quality and coverage. The HiSeq X Ten System now supports the TruSeq® DNA PCR-Free Sample Preparation Kit, which eliminates amplification during library preparation for industry-best coverage of challenging genomic regions with a shortened gel-free workflow. The system continues to support the TruSeq® Nano DNA Sample Preparation Kit, for efficient sequencing of samples with limited available DNA. Together, the reagent kits and library preparation options deliver exceptional genome coverage enabling highly accurate and comprehensive variant calling while continuing to offer human whole-genome sequencing at the $1,000 price point, including instrument depreciation.

“We are excited about the progress and evolution of the HiSeq X Ten System,” said Sheila Fisher, Director, Operations and Development, Genomics Platform at the Broad Institute. “The improvements we’ve seen with the new reagents, combined with support for TruSeq PCR-free, will further benefit the studies we are undertaking with the HiSeq X Ten System.”

For HiSeq 2500 Systems, the HiSeq Rapid v2 Reagent Kit allows the generation of 2x250 base pair, paired-end reads and delivers up to 300 gigabases of data in 60 hours using rapid run mode. The expanded read lengths provide researchers with the ability to more accurately identify gene fusions and tackle more complex metagenomics, and de novo assembly projects. Building on the production power of the HiSeq 2500 System, the new reagents further increase the range of sequencing applications available on the platform and create opportunities for innovative studies in agrigenomics, microbial genomics, cancer genomics, and other areas. The enhancements will work on all HiSeq 2500, HiSeq 1500 and upgraded systems.

“The combined read length of the new 2x250 base pair protocol allows for high confidence identification of taxa in metagenomic analysis. The sheer amount of data from a single lane will satisfy most sequencing needs for any microbial community,” said Stephan Schuster, Professor of Biological Sciences, Nanyang Technological University.

“The launch of the HiSeq X HD v2 Reagent Kit and HiSeq Rapid v2 Reagent Kit demonstrates Illumina’s ongoing commitment to improving our core sequencing technologies and enables our customers to generate the highest-quality genome sequence data,” said Kirk Malloy, Senior Vice President and General Manager, Life Sciences at Illumina. “We look forward to continuing to build on the success of the HiSeq product family as we empower our customers to unlock the power of the genome.”

The HiSeq X HD v2 Reagent Kits and the HiSeq Rapid v2 Reagent Kits will begin shipping in November 2014. To learn more, visit www.Illumina.com/HiSeqXTenUpdates and www.illumina.com/HiSeq2500Updates.

About Illumina

Illumina is transforming human health as the global leader in sequencing and array-based technologies. The company serves customers in a broad range of markets, enabling the universal adoption of genomic solutions in research and clinical settings. To learn how Illumina is unlocking the power of the genome, visit www.illumina.com and follow @illumina.

Forward-Looking Statements

This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.

Source: Illumina, Inc.

Illumina, Inc.
Investor Contact:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media Contact:
Jennifer Temple
858-882-6822
pr@illumina.com